Fiera Capital Corp Has $39.16 Million Stake in Supernus Pharmaceuticals, Inc. (SUPN)

Fiera Capital Corp reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 8.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 908,643 shares of the specialty pharmaceutical company’s stock after selling 87,719 shares during the period. Fiera Capital Corp owned 1.80% of Supernus Pharmaceuticals worth $39,163,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of SUPN. BlackRock Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 156,173.3% during the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after purchasing an additional 6,692,025 shares during the period. Emerald Advisers Inc. PA purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $21,474,000. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $17,553,000. Hodges Capital Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $17,220,000. Finally, Rice Hall James & Associates LLC boosted its holdings in shares of Supernus Pharmaceuticals by 24.5% during the second quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock worth $58,675,000 after purchasing an additional 267,971 shares during the period. Institutional investors own 95.38% of the company’s stock.

In related news, VP Padmanabh P. Bhatt sold 3,735 shares of the business’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total transaction of $167,701.50. Following the completion of the transaction, the vice president now owns 21,209 shares in the company, valued at approximately $952,284.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 2,556 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $44.90, for a total transaction of $114,764.40. Following the transaction, the vice president now owns 24,944 shares of the company’s stock, valued at approximately $1,119,985.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 160,000 shares of company stock valued at $7,505,574. 6.70% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Fiera Capital Corp Has $39.16 Million Stake in Supernus Pharmaceuticals, Inc. (SUPN)” was first posted by Markets Daily and is the property of of Markets Daily. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.themarketsdaily.com/2017/09/13/fiera-capital-corp-has-39-16-million-stake-in-supernus-pharmaceuticals-inc-supn.html.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) remained flat at $48.35 during trading on Wednesday. 72,062 shares of the company traded hands. The firm has a market capitalization of $2.45 billion, a PE ratio of 24.39 and a beta of 1.30. The company has a 50 day moving average of $43.68 and a 200-day moving average of $37.06. Supernus Pharmaceuticals, Inc. has a one year low of $17.25 and a one year high of $49.95.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.24 by $0.08. The firm had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current fiscal year.

SUPN has been the subject of a number of research reports. Jefferies Group LLC increased their price target on shares of Supernus Pharmaceuticals from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, May 31st. Piper Jaffray Companies raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $30.00 to $44.00 in a research note on Thursday, June 1st. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Cantor Fitzgerald increased their price target on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a research note on Wednesday, July 5th. Finally, Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price target for the company in a research note on Thursday, July 13th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $48.29.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply